Biological Engineering Co., Ltd. Shanghai Branch of China was founded in 1981, is the largest industrial base of medical diagnostics. After many years of accumulation, Kehua vitro clinical diagnosis has become the industry leading enterprises.

Kehua is the first diagnosis listed on the Shenzhen Stock Exchange supplies professional company, financial product development, production and sales, with a complete industrial chain of medical diagnostics. Our main business covers the in vitro diagnostic reagents, medical testing equipment, vacuum blood collection system, three main areas.

As R & D-driven high-tech companies, biotechnology companies rely on innovation centers and post-doctoral research station, created in vitro clinical diagnostic reagents and automated diagnostic instrument developed two technology platforms, step by step reagent and equipment of the "series", "integration" development goals; the company product line extension strategy with remarkable results: more than one hundred products have obtained approval, 56 reagents and equipment products through the European CE certification, the main domestic market share tied for first place; the company to create the most outstanding marketing network, and expand international markets, Branch, foreign brand products have been exported to 22 countries and regions, HIV diagnostic reagents are included in the World Health Organization, UNICEF, the United States President of the Fund's procurement list of internationally renowned institutions, and with the Clinton Foundation signed a long-term supply contracts.

Internally and externally, fine Zhi Yuan. The future, Branch, will continue adhering to the "love of life, the pursuit of excellence" corporate purposes, to the basic talent to professional, as the international focus to the capital market as the basis, to create renowned Chinese and foreign, "Kehua" brand, Foundation seeking a hundred years. Management will continue based on the rational and prudent management style, focusing on the development of financial security and the stability to its customers and investors to create long-term, sustainable value growth and performance in return for China's overall rise of laboratory medicine and industry best to go.